Corbus Pharmaceuticals Holdings (CRBP) Operating Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings' Operating Expenses history runs 13 years deep, the most recent figure standing at $24.4 million for Q3 2025.

• On a quarterly basis, Operating Expenses rose 57.48% year-over-year to $24.4 million in Q3 2025; TTM through Dec 2025 was $63.3 million, a 30.01% increase from a year earlier, with the FY2024 full-year figure at $48.7 million, up 8.08% from the prior year.
• Operating Expenses advanced to $24.4 million in Q3 2025 per CRBP's latest filing, from $19.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $24.4 million in Q3 2025 and bottomed at $8.2 million in Q3 2022.
• The 5-year median for Operating Expenses is $12.3 million (2022), against an average of $13.4 million.
• Across the five-year window, Operating Expenses plunged 60.31% in 2021 and jumped 105.5% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $10.0 million in 2021, then advanced by 7.99% to $10.8 million in 2022, then fell by 6.42% to $10.1 million in 2023, then rose by 24.75% to $12.6 million in 2024, then soared by 93.71% to $24.4 million in 2025.
• Per Business Quant, the three latest CRBP Operating Expenses figures stand at $24.4 million (Q3 2025), $19.2 million (Q2 2025), and $19.8 million (Q1 2025).